Severe influenza cases
RecordSTO-01M2KJ7XCG-3Y4BJ2059J-BJMGGG
Global · 2026
Severe influenza cases were up to 5 million in 2026 (GSK).
Severe influenza cases: every country and year, and how it is measured
- Publisher
- GSK
- Authority tier
- T3 Research
- Report
- GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data
- Locator
- About seasonal flu
- Retrieved
- 15 Sep 2026
- Status
- Verified
What the source says
Seasonal influenza causes around one billion cases globally each year, including up to 5 million cases of severe illness and up to 650,000 respiratory deaths.
Checked: the figure 5 millionis stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
GSK. (2026). GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data. Retrieved September 15, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGG
Other formats: MLA, Chicago, BibTeX
- MLA
- GSK. "GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data." 2026, https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGG.
- Chicago
- GSK. "GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data." 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGG.
- BibTeX
- @misc{gsk2026severebjmggg, author = {{GSK}}, title = {GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGG}, note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed September 15, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- GSK · homepage ↗
- Authority tier
- Tier 3 · Research and companies
- Report
- GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data
- Type
- Press release
- Published
- —
- Locator
- About seasonal flu
- Retrieved
- 15 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification
- Status
- Verified
- Review protocol
- Editorial review
- Checked on
- 15 September 2026
- Last revision
- 27 September 2026
- Permanent URL
- /stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGG